Follow-up and outcomes
EVENT
The overall follow-up period in this study was 90 days for each patient after the index event. Neurological function outcomes were assessed by modifying Rankins Scale (mRS) [Patients enrolled in this study were divided into the favorable outcome group (mRS 0–1) and the unfavorable outcome group (mRS 2–6). Anticoagulants after EVT include low molecular weight heparin (LMWH) and/or direct oral anticoagulants (DOACs) including new oral anticoagulants (NOACs) (rivaroxaban, dabigatran etexilate, etc.) or Vitamin K antagonists (VKAs) (warfarin, etc.).